Відмінності між версіями «Harmacol. 2011;254:267?9. Tannock IF, de Wit R, Berry WR, et al. Docetaxel»

Матеріал з HistoryPedia
Перейти до: навігація, пошук
(Створена сторінка: Lancet. 2010;376:1147?4. Quach JM, Askmyr M, Jovic T, et al. Myelosuppressive therapies drastically improve pro-inflammatory cytokines and directly bring about...)
 
м
 
Рядок 1: Рядок 1:
−
Lancet. 2010;376:1147?4. Quach JM, Askmyr M, Jovic T, et al. Myelosuppressive therapies drastically improve pro-inflammatory cytokines and directly bring about bone loss. J Bone Miner Res. 2014; doi: 10.1002/jbmr.2415. This study discovered that myelosuppresive chemotherapies directly cause bone loss. Shandala T, Shen NY, Hopwood B, et al. The part of osteocyte apoptosis in cancer chemotherapy-induced bone loss. J Cell Physiol. 2012;227:2889?7. Georgiou KR, King TJ, Scherer MA, et al. Attenuated Wnt/betacatenin signalling mediates methotrexate chemotherapy-induced bone loss and marrow adiposity in rats. Bone. 2012;50:1223?three. Tipples K, Robinson A. Optimal management of cancer treatmentinduced bone loss: considerations for elderly patients. Drugs Aging. 2011;28:867?three. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci. 2002;966:73?1. Williams HJ, Davies AM. The impact of X-rays on bone: a pictorial review. Eur Radiol. 2006;16:619?three. Matsumura S, Jikko A, Hiranuma H, et al. Effect of X-ray irradiation on proliferation and differentiation of osteoblast. Calcif Tissue Int. 1996;59:307?. Szymczyk KH, Shapiro IM, Adams CS. Ionizing radiation sensitizes bone cells to apoptosis. Bone. 2004;34:148?six. Chandra A, Lin T, Tribble MB, et al. PTH1-34 alleviates radiotherapy-induced regional bone loss by improving osteoblast and osteocyte survival.Harmacol. 2011;254:267?9. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502?2. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing [http://www.medchemexpress.com/Losmapimod.html SB856553 biological activity] following docetaxel remedy: a randomised open-label trial. Lancet. 2010;376:1147?4. Quach JM, Askmyr M, Jovic T, et al. Myelosuppressive therapies substantially boost pro-inflammatory cytokines and directly lead to bone loss. J Bone Miner Res. 2014; doi: ten.1002/jbmr.2415. This study discovered that myelosuppresive chemotherapies straight result in bone loss. Shandala T, Shen NY, Hopwood B, et al. The function of osteocyte apoptosis in cancer chemotherapy-induced bone loss. J Cell Physiol. 2012;227:2889?7. Georgiou KR, King TJ, Scherer MA, et al. Attenuated Wnt/betacatenin signalling mediates methotrexate chemotherapy-induced bone loss and marrow adiposity in rats. Bone. 2012;50:1223?3. Tipples K, Robinson A. Optimal management of cancer treatmentinduced bone loss: considerations for elderly sufferers. Drugs Aging. 2011;28:867?three. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci. 2002;966:73?1. Williams HJ, Davies AM. The impact of X-rays on bone: a pictorial review. Eur Radiol. 2006;16:619?three. Matsumura S, Jikko A, Hiranuma H, et al. Impact of X-ray irradiation on proliferation and differentiation of osteoblast. Calcif Tissue Int. 1996;59:307?. Szymczyk KH, Shapiro IM, Adams CS. Ionizing radiation sensitizes bone cells to apoptosis. Bone. 2004;34:148?six. Chandra A, Lin T, Tribble MB, et al. PTH1-34 alleviates radiotherapy-induced neighborhood bone loss by improving osteoblast and osteocyte survival. Bone. 2014;67:33?0. Gives a summary of studies within the introduction concerning radiotherapy-induced alterations in osteoclast number and activity. Indicates that PTH1-34 might alleviate radiotherapy-induced bone loss by enhancing osteoblast and osteocyte survival.
+
2011;28:867?three. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci. 2002;966:73?1. Williams HJ, Davies AM. The effect of X-rays on bone: a pictorial assessment. Eur Radiol. 2006;16:619?three. Matsumura S, Jikko A, Hiranuma H, et al. Effect of X-ray irradiation on proliferation and differentiation of osteoblast. Calcif Tissue Int. 1996;59:307?. Szymczyk KH, Shapiro IM, Adams CS. Ionizing radiation sensitizes bone cells to apoptosis. Bone. 2004;34:148?six. Chandra A, Lin T, Tribble MB, et al. PTH1-34 alleviates [http://www.medchemexpress.com/PD0325901.html PD325901 price] radiotherapy-induced regional bone loss by enhancing osteoblast and osteocyte survival. Bone. 2014;67:33?0. Gives a summary of research in the introduction regarding radiotherapy-induced adjustments in osteoclast quantity and activity. Indicates that PTH1-34 may alleviate radiotherapy-induced bone loss by enhancing osteoblast and osteocyte survival. Manas A, Casas F, Ciria JP, et al. Randomised study of single dose (eight Gy vs. six Gy) of analgesic radiotherapy plus zoledronic acid in [http://www.medchemexpress.com/Oxaliplatin.html Oxaliplatin manufacturer] patients with bone metastases. Clin Transl Oncol. 2008;10:281?. Willey JS, Livingston EW, Robbins ME, et al. Risedronate prevents early radiation-induced osteoporosis in mice at various skeletal places. Bone. 2010;46:101?1. Keenawinna L, Oest ME, Mann [https://dx.doi.org/10.1016/j.addbeh.2012.10.012 title= j.addbeh.2012.ten.012] KA, et al. Zoledronic acid prevents loss of trabecular bone soon after focal irradiation in mice. Radiat Res. 2013;180:89?9. Longo J, Lutz S, Johnstone C. Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, valuable for individuals with osteoblastic bone metastases. Cancer Manag Res. 2013;five:235?two. Roque IF, Martinez-Zapata MJ, Scott-Brown M, et al. Radioisotopes for metastatic bone discomfort. Cochrane Database Syst Rev. 2011; CD003347. Wissing MD, van Leeuwen FW, van der Pluijm G, et al. Radium223 chloride: extending life in prostate cancer sufferers by treating bone metastases. Clin Cancer Res. 2013;19:5822?. Summary of radium-223 in prostate cancer sufferers, and the limitations of presently reported clinical research with this novel therapy. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival [https://dx.doi.org/10.1111/cdev.12038 title= cdev.12038] in metastatic prostate cancer. N Engl J Med. 2013;369: 213?three.Harmacol. 2011;254:267?9. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for sophisticated prostate cancer. N Engl J Med. 2004;351:1502?two. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing following docetaxel therapy: a randomised open-label trial. Lancet. 2010;376:1147?four. Quach JM, Askmyr M, Jovic T, et al. Myelosuppressive therapies significantly boost pro-inflammatory cytokines and directly lead to bone loss. J Bone Miner Res. 2014; doi: ten.1002/jbmr.2415. This study found that myelosuppresive chemotherapies straight bring about bone loss. Shandala T, Shen NY, Hopwood B, et al. The part of osteocyte apoptosis in cancer chemotherapy-induced bone loss. J Cell Physiol. 2012;227:2889?7. Georgiou KR, King TJ, Scherer MA, et al. Attenuated Wnt/betacatenin signalling mediates methotrexate chemotherapy-induced bone loss and marrow adiposity in rats. Bone. 2012;50:1223?3. Tipples K, Robinson A. Optimal management of cancer treatmentinduced bone loss: considerations for elderly patients.

Поточна версія на 04:36, 3 лютого 2018

2011;28:867?three. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci. 2002;966:73?1. Williams HJ, Davies AM. The effect of X-rays on bone: a pictorial assessment. Eur Radiol. 2006;16:619?three. Matsumura S, Jikko A, Hiranuma H, et al. Effect of X-ray irradiation on proliferation and differentiation of osteoblast. Calcif Tissue Int. 1996;59:307?. Szymczyk KH, Shapiro IM, Adams CS. Ionizing radiation sensitizes bone cells to apoptosis. Bone. 2004;34:148?six. Chandra A, Lin T, Tribble MB, et al. PTH1-34 alleviates PD325901 price radiotherapy-induced regional bone loss by enhancing osteoblast and osteocyte survival. Bone. 2014;67:33?0. Gives a summary of research in the introduction regarding radiotherapy-induced adjustments in osteoclast quantity and activity. Indicates that PTH1-34 may alleviate radiotherapy-induced bone loss by enhancing osteoblast and osteocyte survival. Manas A, Casas F, Ciria JP, et al. Randomised study of single dose (eight Gy vs. six Gy) of analgesic radiotherapy plus zoledronic acid in Oxaliplatin manufacturer patients with bone metastases. Clin Transl Oncol. 2008;10:281?. Willey JS, Livingston EW, Robbins ME, et al. Risedronate prevents early radiation-induced osteoporosis in mice at various skeletal places. Bone. 2010;46:101?1. Keenawinna L, Oest ME, Mann title= j.addbeh.2012.ten.012 KA, et al. Zoledronic acid prevents loss of trabecular bone soon after focal irradiation in mice. Radiat Res. 2013;180:89?9. Longo J, Lutz S, Johnstone C. Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, valuable for individuals with osteoblastic bone metastases. Cancer Manag Res. 2013;five:235?two. Roque IF, Martinez-Zapata MJ, Scott-Brown M, et al. Radioisotopes for metastatic bone discomfort. Cochrane Database Syst Rev. 2011; CD003347. Wissing MD, van Leeuwen FW, van der Pluijm G, et al. Radium223 chloride: extending life in prostate cancer sufferers by treating bone metastases. Clin Cancer Res. 2013;19:5822?. Summary of radium-223 in prostate cancer sufferers, and the limitations of presently reported clinical research with this novel therapy. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival title= cdev.12038 in metastatic prostate cancer. N Engl J Med. 2013;369: 213?three.Harmacol. 2011;254:267?9. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for sophisticated prostate cancer. N Engl J Med. 2004;351:1502?two. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing following docetaxel therapy: a randomised open-label trial. Lancet. 2010;376:1147?four. Quach JM, Askmyr M, Jovic T, et al. Myelosuppressive therapies significantly boost pro-inflammatory cytokines and directly lead to bone loss. J Bone Miner Res. 2014; doi: ten.1002/jbmr.2415. This study found that myelosuppresive chemotherapies straight bring about bone loss. Shandala T, Shen NY, Hopwood B, et al. The part of osteocyte apoptosis in cancer chemotherapy-induced bone loss. J Cell Physiol. 2012;227:2889?7. Georgiou KR, King TJ, Scherer MA, et al. Attenuated Wnt/betacatenin signalling mediates methotrexate chemotherapy-induced bone loss and marrow adiposity in rats. Bone. 2012;50:1223?3. Tipples K, Robinson A. Optimal management of cancer treatmentinduced bone loss: considerations for elderly patients.

Отримано з http://istoriya.soippo.edu.ua/index.php?title=Harmacol._2011;254:267%3F9._Tannock_IF,_de_Wit_R,_Berry_WR,_et_al._Docetaxel&oldid=283319